Lilly plays up Cyramza's biomarker edge in crowded liver cancer field

It’s been a long road for Eli Lilly’s Cyramza in liver cancer after it belly-flopped a phase 3 trial five years ago. On the back of a successful second attempt, the drugmaker has finally accomplished what once seemed out of reach.